Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.62 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3519020 | 0.98 | ALDH1A1 (0.69) | ALDH1A1USP2LMNAL3MBTL1MAPT | |
| SCHEMBL9725963 | 0.88 | ALDH1A1 (0.67) | ALDH1A1USP2LMNAMAPTNPSR1 | |
| SCHEMBL4791742 | 0.87 | KMT2A (0.67) | ALDH1A1USP2LMNAL3MBTL1MAPT | |
| SCHEMBL8229849 | 0.84 | ALDH1A1 (0.64) | ALDH1A1LMNAMAPTNPSR1GPR55 | |
| SCHEMBL19403443 | 0.82 | PSMD14 (0.75) | ALDH1A1LMNAL3MBTL1MAPTNPSR1 | |
| SCHEMBL8234215 | 0.81 | MEN1 (0.60) | ALDH1A1USP2LMNAL3MBTL1MAPT | |
| SCHEMBL8226106 | 0.81 | USP2 (0.54) | ALDH1A1USP2LMNAL3MBTL1MAPT | |
| SCHEMBL11887749 | 0.81 | PTGDR2 (0.75) | ALDH1A1L3MBTL1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL3515589 | 0.80 | USP2 (0.53) | ALDH1A1USP2LMNAL3MBTL1MAPT | |
| Hydrochloric Acid SCHEMBL3516384 | 0.80 | MEN1 (0.58) | ALDH1A1USP2LMNAL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029736-A1 | 2-SUBSTITUTED PROLINE BIS-AMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-20090118200-A1 | Proline bis-amide orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2009-05-07 | — | — | US | disclosed |
| US-20090118200-A1 | Proline bis-amide orexin receptor antagonists | MERCK SHARP & DOHME CORP. | 2009-05-07 | — | — | US | disclosed |
| US-20080293745-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | SANOFI-AVENTIS (FR) | 2008-11-27 | — | — | US | disclosed |
| US-20080280963-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | SANOFI-AVENTIS (FR) | 2008-11-13 | — | — | US | disclosed |
| EP-1931627-A1 | AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIGANDS | Sanofi-Aventis (FR) | 2008-06-18 | — | — | EP | disclosed |
| EP-1888563-A1 | PROLINE BIS-AMIDE OREXIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2008008551-A2 | 2-SUBSTITUTED PROLINE BIS-AMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007034251-A1 | AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIGANDS | SANOFI-AVENTIS (FR) | 2007-03-29 | — | — | WO | disclosed |
| WO-2006127550-A1 | PROLINE BIS-AMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006127550-A1 | PROLINE BIS-AMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293745-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | CCR3, CCR1, CCR4 | ALDH1A1 1778/4885USP2 2969/4885LMNA 3402/4885 |
| US-20090118200-A1 | Proline bis-amide orexin receptor antagonists | HCRTR1, HCRTR2, NPSR1 | ALDH1A1 3973/4885USP2 2073/4885LMNA 2459/4885 |
| US-20080280963-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | CCR3, CCR1, CCR4 | ALDH1A1 1778/4885USP2 2969/4885LMNA 3402/4885 |
| US-20100029736-A1 | 2-SUBSTITUTED PROLINE BIS-AMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | ALDH1A1 3827/4885USP2 1566/4885LMNA 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.